Peregrine Capital Management LLC Novo Cure LTD Transaction History

Peregrine Capital Management LLC

$3.18 Billion
Q4 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 26, 2023	BUY	$56.44 - $118.81 $405,408 - $853,412	7,183 Added 21.82%	40,095 $2.41 Million
Q4 2022 Jan 10, 2023	SELL	$63.98 - $85.37 $506,593 - $675,959	-7,918 Reduced 19.39%	32,912 $2.41 Million
Q3 2022 Oct 26, 2022	SELL	$67.99 - $89.57 $154,201 - $203,144	-2,268 Reduced 5.26%	40,830 $3.1 Million
Q2 2022 Jul 20, 2022	SELL	$56.6 - $89.9 $1,528 - $2,427	-27 Reduced 0.06%	43,098 $3 Million
Q1 2022 Apr 27, 2022	SELL	$60.15 - $84.52 $188,810 - $265,308	-3,139 Reduced 6.78%	43,125 $3.57 Million
Q4 2021 Jan 31, 2022	BUY	$75.08 - $121.99 $668,061 - $1.09 Million	8,898 Added 23.81%	46,264 $3.47 Million
Q3 2021 Nov 02, 2021	SELL	$116.17 - $194.55 $857,450 - $1.44 Million	-7,381 Reduced 16.49%	37,366 $4.34 Million
Q2 2021 Aug 03, 2021	SELL	$130.4 - $225.58 $3.67 Million - $6.35 Million	-28,133 Reduced 38.6%	44,747 $9.93 Million
Q1 2021 May 11, 2021	SELL	$124.11 - $190.17 $362,028 - $554,725	-2,917 Reduced 3.85%	72,880 $9.63 Million
Q4 2020 Jan 19, 2021	SELL	$112.16 - $174.14 $5.69 Million - $8.83 Million	-50,699 Reduced 40.08%	75,797 $13.1 Million
Q3 2020 Oct 20, 2020	SELL	$58.05 - $111.31 $3.65 Million - $7 Million	-62,908 Reduced 33.21%	126,496 $14.1 Million
Q2 2020 Jul 30, 2020	BUY	$57.2 - $74.41 $2.21 Million - $2.88 Million	38,715 Added 25.69%	189,404 $11.2 Million
Q1 2020 Apr 17, 2020	BUY	$57.05 - $95.75 $31,605 - $53,045	554 Added 0.37%	150,689 $10.1 Million
Q4 2019 Jan 16, 2020	SELL	$68.3 - $93.8 $123,418 - $169,496	-1,807 Reduced 1.19%	150,135 $12.7 Million
Q3 2019 Oct 16, 2019	SELL	$61.86 - $97.8 $3.13 Million - $4.96 Million	-50,675 Reduced 25.01%	151,942 $11.4 Million
Q2 2019 Jul 18, 2019	SELL	$42.22 - $63.23 $974,775 - $1.46 Million	-23,088 Reduced 10.23%	202,617 $0
Q1 2019 Apr 12, 2019	SELL	$31.96 - $56.12 $5.04 Million - $8.85 Million	-157,716 Reduced 41.13%	225,705 $0
Q4 2018 Jan 17, 2019	SELL	$28.72 - $52.63 $2.16 Million - $3.95 Million	-75,138 Reduced 16.39%	383,421 $12.8 Million
Q3 2018 Oct 18, 2018	SELL	$32.0 - $52.4 $13.2 Million - $21.6 Million	-412,470 Reduced 47.35%	458,559 $0
Q2 2018 Jul 12, 2018	SELL	$19.85 - $32.0 $1.02 Million - $1.65 Million	-51,439 Reduced 5.58%	871,029 $0
Q1 2018 Apr 16, 2018	BUY	$19.3 - $23.65 $1.1 Million - $1.34 Million	56,797 Added 6.56%	922,468 $0
Q4 2017 Jan 24, 2018	BUY	$16.3 - $21.9 $3.88 Million - $5.22 Million	238,195 Added 37.96%	865,671 $0
Q3 2017 Oct 25, 2017	BUY	$18.05 - $21.75 $11.3 Million - $13.6 Million	627,476	627,476 $0

Others Institutions Holding NVCR

# of Institutions

290

Shares Held

75.2M

Call Options Held

1.81M

Put Options Held

464K

Black Rock Inc. New York, NY

12.1M
Shares

$273 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.8M
Shares

$265 Million
0.01% of portfolio
Capital International Investors Los Angeles, CA

8.87M
Shares

$199 Million
0.05% of portfolio
Capital World Investors Los Angeles, CA

4.82M
Shares

$108 Million
0.02% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

2.74M
Shares

$61.6 Million
5.68% of portfolio

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.36B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.

Account